Laboratory of Cancer Biology, Key lab of Biotherapy in Zhejiang Province, Cancer Institute of Zhejiang University, Sir Run Run Shaw hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310016, China.
Department of Radiation Oncology, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, 310016, China.
Signal Transduct Target Ther. 2020 Nov 20;5(1):270. doi: 10.1038/s41392-020-00347-9.
Cancer immunotherapy especially immune checkpoint inhibition has achieved unprecedented successes in cancer treatment. However, there are many patients who failed to benefit from these therapies, highlighting the need for new combinations to increase the clinical efficacy of immune checkpoint inhibitors. In this review, we summarized the latest discoveries on the combination of nucleic acid-sensing immunity and immune checkpoint inhibitors in cancer immunotherapy. Given the critical role of nuclear acid-mediated immunity in maintaining the activation of T cell function, it seems that harnessing the nuclear acid-mediated immunity opens up new strategies to enhance the effect of immune checkpoint inhibitors for tumor control.
癌症免疫疗法，特别是免疫检查点抑制，在癌症治疗方面取得了前所未有的成功。然而，仍有许多患者无法从这些疗法中获益，这凸显了需要新的联合方案来提高免疫检查点抑制剂的临床疗效。在这篇综述中，我们总结了核酸感应免疫与免疫检查点抑制剂在癌症免疫治疗中的最新联合研究发现。鉴于核酸介导的免疫在维持 T 细胞功能激活方面的关键作用，利用核酸介导的免疫似乎为增强免疫检查点抑制剂的肿瘤控制效果开辟了新的策略。
